BioSpace News Archive

HUTCHMED Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to amdizalisib, a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin’s lymphoma.

ZOLL® Medical Corporation and Itamar™ Medical Ltd. announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.

ITM AG, a leading radiopharmaceutical biotech company, announced that it has signed a strategic long-term agreement to create a Joint Venture with Chengdu Gaotong Isotope Co. Ltd., the leading provider of radiopharmaceuticals and nuclear services in China and a subsidiary of ITM’s collaboration partner China Isotope and Radiation Corporation.

Marseille, France,September 13, 2021 – ImCheck Therapeutics announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa trial evaluating ICT01, a first-in-class Butyrophilin 3A-targeting monoclonal antibody, in patients with advanced, relapsed/refractory solid and hematological cancers, in an oral presentation at the ESMO Congress 2021.

Everest Medicines Limited announced two separate definitive agreements with Providence Therapeutics Holdings Inc. to license rights to Providence’s mRNA COVID-19 vaccine candidates in Asia emerging markets, including Greater China, Southeast Asia and Pakistan, and establish a broad, strategic partnership to develop mRNA products globally leveraging Providence’s cutting-edge mRNA technology platform.

Providence Therapeutics Holdings Inc. announced two separate definitive agreements with Everest Medicines Limited, to license rights to Providence’s mRNA COVID-19 vaccine candidates in emerging markets in Asia, including Greater China, Southeast Asia and Pakistan, and establish a broad, strategic partnership to develop mRNA products globally leveraging Providence’s cutting-edge mRNA technology platform.

Amarin Corporation plc announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021.

VistaGen Therapeutics, Inc. announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with social anxiety disorder.

The signing of the manufacturing agreement with NeuExcell showcases our flexibility in supporting biotech companies of all sizes, and our focused commitment to enabling NeuExcell to reach the full potential of their innovative gene technology platform on accelerated timelines.

Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy.